Display search results for ** instead (5 products)
24 Aug 2016  |  North America
A Deep Dive into Twelve Prominent Solutions
Not all customers, locations or users will move to cloud communications services. There are valid reasons to deploy UC solution on the customer premises. This Buyers' Guide overviews capabilities available with the flagship SMB platforms offered by North America's leading UC platform vendors. Details include: development direction, scale, performan...
USD 7,500.00 save 25 %
04 Jul 2016  |  North America
The Next Generation of Cancer Therapies
Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibi...
USD 6,000.00 save 25 %
16 Aug 2016  |  North America
Emerging Business Models Drive Transformation
The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses—and to understand the value chain from clinical to c...
USD 5,250.00 save 25 %
03 May 2016  |  North America
Massive Gains for Vendors Who Can Win the Race to Identify Key Elements of Successful Cyber Defense Platforms
In 2015, network access control (NAC) proved to be among the most successful cyber defense platforms as NAC vendors experienced 30% YoY growth in revenues for appliances and related services. Frost & Sullivan anticipates continuing demand for NAC through 2020. NAC is a technology that can be used to provide immediate mitigation from cyber threats b...
USD 4,875.00 save 25 %
11 Nov 2016  |  North America
High Pricing and Undefined Reimbursement Policies will Limit the Sales of Orphan Drugs
The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...
USD 4,500.00 save 25 %